309 related articles for article (PubMed ID: 23072659)
1. Cost effectiveness of oromucosal cannabis-based medicine (Sativex®) for spasticity in multiple sclerosis.
Lu L; Pearce H; Roome C; Shearer J; Lang IA; Stein K
Pharmacoeconomics; 2012 Dec; 30(12):1157-71. PubMed ID: 23072659
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.
Slof J; Ruiz L; Vila C
Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):379-91. PubMed ID: 25771713
[TBL] [Abstract][Full Text] [Related]
3. Sativex® in multiple sclerosis spasticity: a cost-effectiveness model.
Slof J; Gras A
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):439-41. PubMed ID: 22681512
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis.
Mantovani LG; Cozzolino P; Cortesi PA; Patti F;
Clin Drug Investig; 2020 Apr; 40(4):319-326. PubMed ID: 32130684
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Gras A; Broughton J
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):771-779. PubMed ID: 26750641
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.
Freidel M; Tiel-Wilck K; Schreiber H; Prechtl A; Essner U; Lang M
Acta Neurol Scand; 2015 Jan; 131(1):9-16. PubMed ID: 25208898
[TBL] [Abstract][Full Text] [Related]
7. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.
Flachenecker P
Expert Rev Neurother; 2013 Feb; 13(3 Suppl 1):15-9. PubMed ID: 23369055
[TBL] [Abstract][Full Text] [Related]
8. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
Squintani G; Donato F; Turri M; Deotto L; Teatini F; Moretto G; Erro R
J Neurol Sci; 2016 Nov; 370():263-268. PubMed ID: 27772772
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses.
Oppe M; Ortín-Sulbarán D; Vila Silván C; Estévez-Carrillo A; Ramos-Goñi JM
Eur J Health Econ; 2021 Jul; 22(5):711-721. PubMed ID: 33880663
[TBL] [Abstract][Full Text] [Related]
10. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS.
Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J
Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310
[TBL] [Abstract][Full Text] [Related]
11. Sativex(®) (tetrahydrocannabinol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data.
Vermersch P
Expert Rev Neurother; 2011 Apr; 11(4 Suppl):15-9. PubMed ID: 21449855
[TBL] [Abstract][Full Text] [Related]
12. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
13. Clinical case reviews and poster sessions in multiple sclerosis spasticity: main outcomes and highlights.
Trojano M; Celius EG; Donzé C; Izquierdo G; Patti F; Pöhlau D
Eur Neurol; 2014; 72 Suppl 1():15-9. PubMed ID: 25278119
[TBL] [Abstract][Full Text] [Related]
14. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study).
Messina S; Solaro C; Righini I; Bergamaschi R; Bonavita S; Bossio RB; Brescia Morra V; Costantino G; Cavalla P; Centonze D; Comi G; Cottone S; Danni MC; Francia A; Gajofatto A; Gasperini C; Zaffaroni M; Petrucci L; Signoriello E; Maniscalco GT; Spinicci G; Matta M; Mirabella M; Pedà G; Castelli L; Rovaris M; Sessa E; Spitaleri D; Paolicelli D; Granata A; Zappia M; Patti F;
PLoS One; 2017; 12(8):e0180651. PubMed ID: 28763462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity.
Patti F; Messina S; Solaro C; Amato MP; Bergamaschi R; Bonavita S; Bruno Bossio R; Brescia Morra V; Costantino GF; Cavalla P; Centonze D; Comi G; Cottone S; Danni M; Francia A; Gajofatto A; Gasperini C; Ghezzi A; Iudice A; Lus G; Maniscalco GT; Marrosu MG; Matta M; Mirabella M; Montanari E; Pozzilli C; Rovaris M; Sessa E; Spitaleri D; Trojano M; Valentino P; Zappia M;
J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):944-51. PubMed ID: 27160523
[TBL] [Abstract][Full Text] [Related]
16. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.
Syed YY; McKeage K; Scott LJ
Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907
[TBL] [Abstract][Full Text] [Related]
17. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
D'hooghe M; Willekens B; Delvaux V; D'haeseleer M; Guillaume D; Laureys G; Nagels G; Vanderdonckt P; Van Pesch V; Popescu V
BMC Neurol; 2021 Jun; 21(1):227. PubMed ID: 34157999
[TBL] [Abstract][Full Text] [Related]
18. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
19. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain.
Barnes MP
Expert Opin Pharmacother; 2006 Apr; 7(5):607-15. PubMed ID: 16553576
[TBL] [Abstract][Full Text] [Related]
20. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
Haupts M; Vila C; Jonas A; Witte K; Álvarez-Ossorio L
Eur Neurol; 2016; 75(5-6):236-43. PubMed ID: 27160412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]